- Indigenously designed Supernova Stent Retriever proves global-grade outcomes in acute brain stroke
Eight Indian hospitals deliver robust clinical evidence for mechanical thrombectomy
Make in India milestone brings affordable, timely stroke care within reach
Marengo CIMS leads the way in advanced neurovascular innovation
NE HEALTH BUREAU
AHMEDABAD, DEC 18
India has marked a defining moment in advanced stroke care with the successful completion of the GRASSROOT Trial, a landmark multicentre clinical study validating the Supernova Stent Retriever, an indigenously developed device for treating acute ischemic stroke caused by large vessel occlusion. The study positions India firmly on the global neurovascular innovation map and reinforces the Make in India vision in high-end medical technology.
At the heart of this achievement is a powerful reality: the stent was designed by Indian engineers and clinically validated entirely within India, across eight leading stroke centres, including Marengo CIMS Hospital. The trial delivers strong Indian clinical evidence that world-class stroke devices can be designed, tested and proven at home, bringing the Make in India dream decisively into acute brain care.
The GRASSROOT Trial confirms that a “Made in India stent is now available for brain vessels in acute brain stroke.” The Supernova stent retriever demonstrated high rates of successful vessel recanalisation, excellent first-pass success, encouraging functional recovery at 90 days, and a low complication profile—outcomes comparable with global benchmarks.
Beyond clinical performance, the innovation addresses a long-standing challenge in India: access and affordability. Stroke remains among the leading causes of death and long-term disability in the country, and timely mechanical thrombectomy can be life-saving. Indigenous, evidence-backed solutions such as Supernova significantly strengthen India’s acute stroke care ecosystem.
Highlighting the clinical impact, Dr Mukesh Sharma, Principal Investigator of the GRASSROOT Trial, Director – Neurointervention & Stroke, Marengo CIMS Hospital, said, “The GRASSROOT Trial is a game-changer for stroke care in India. High reperfusion rates with excellent safety mean more patients can now access life-saving mechanical thrombectomy within critical time windows, especially in resource-constrained settings.”
Dr R. Shankaran, Unit Medical Director, Marengo CIMS Hospital, added, “This study proves that world-class outcomes are achievable with indigenous innovation. It strengthens our confidence in delivering advanced stroke interventions that are timely, safe, and affordable for Indian patients.”
Placing the breakthrough in the broader cardiovascular context, Dr Keyur Parikh, Interventional Cardiologist and Chairman, Marengo CIMS Hospital, stated, “India urgently needs scalable, cost-effective solutions for complex vascular emergencies. The Supernova device and the GRASSROOT Trial represent exactly that — innovation driven by Indian clinical realities, backed by robust scientific evidence.”
Underscoring the institutional commitment behind the milestone, Dr Raajiv Singhal, Founding Member, Managing Director and Group CEO, Marengo Asia Hospitals, said, “At Marengo Asia Hospitals, our approach to innovation is grounded in patient outcomes, evidence, and real-world impact. This milestone reflects our patient-first philosophy and our collective commitment to advancing stroke care through robust, Indian clinical evidence. I compliment the clinicians, researchers, engineers, and partner institutions whose collaboration made this breakthrough possible. By teaching, training, and treating in equal measure, we are building a healthcare ecosystem where excellence is sustainable, accessible, and firmly anchored in trust and outcomes.”
With nearly 1.7 million new stroke cases reported annually in India, the validation of an indigenous, clinically proven stroke device marks a crucial leap in strengthening national stroke preparedness—an effort that Marengo CIMS Hospital continues to lead from the front.
S
